Tharimmune (NASDAQ:THAR – Get Free Report) and Cara Therapeutics (NASDAQ:CARA – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, analyst recommendations, profitability, risk and earnings.
Analyst Ratings
This is a summary of recent ratings and target prices for Tharimmune and Cara Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Tharimmune | 0 | 0 | 1 | 1 | 3.50 |
| Cara Therapeutics | 0 | 5 | 0 | 0 | 2.00 |
Tharimmune presently has a consensus target price of $17.00, suggesting a potential upside of 812.51%. Cara Therapeutics has a consensus target price of $27.84, suggesting a potential upside of 443.75%. Given Tharimmune’s stronger consensus rating and higher possible upside, research analysts clearly believe Tharimmune is more favorable than Cara Therapeutics.
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Tharimmune | N/A | N/A | -$9.32 million | N/A | N/A |
| Cara Therapeutics | $20.97 million | 1.12 | -$118.51 million | ($21.01) | -0.24 |
Tharimmune has higher earnings, but lower revenue than Cara Therapeutics.
Profitability
This table compares Tharimmune and Cara Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Tharimmune | N/A | -167.63% | -130.18% |
| Cara Therapeutics | -1,099.76% | -367.97% | -107.43% |
Insider and Institutional Ownership
1.2% of Tharimmune shares are held by institutional investors. Comparatively, 44.7% of Cara Therapeutics shares are held by institutional investors. 2.4% of Tharimmune shares are held by company insiders. Comparatively, 3.1% of Cara Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Risk and Volatility
Tharimmune has a beta of 1.24, meaning that its stock price is 24% more volatile than the S&P 500. Comparatively, Cara Therapeutics has a beta of 0.5, meaning that its stock price is 50% less volatile than the S&P 500.
Summary
Tharimmune beats Cara Therapeutics on 8 of the 12 factors compared between the two stocks.
About Tharimmune
Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics; and Washington University in St. Louis for the rights to develop and commercialize technology related to multiple hybridomas and antibodies directed specifically towards human HER2. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.
About Cara Therapeutics
Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.
Receive News & Ratings for Tharimmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tharimmune and related companies with MarketBeat.com's FREE daily email newsletter.
